Compare CoMentis vs Neuronascent
Customers evaluate the quality of CoMentis's products using the following success metrics.
CoMentis is 20 yrs old and is based in United States.
CoMentis is focused on developing drugs to treat various central nervous system (CNS) disorders such as Alzheimer's disease and schizophrenia. The company covers the research and development spectrum from initial drug design through manufacturing and clinical trials.
Neuronascent is 20 yrs old and is based in United States.
Neuronascent focuses on the discovery and development of therapies for Alzheimer's disease, depression, and stroke based on the science of neurogenesis. It provides a phenotypic screening platform that uses a pipeline of small-molecule oral regenerative candidates. Neuronascent was founded in 2004 and is based in Clarksville, Maryland.
Information not available because CoMentis has not claimed their profile.
Work for CoMentis? Claim your profile by submitting an Analyst Briefing. By submitting you can
Work for CoMentis?
Claim your profile now.
Why Neuronascent beats CoMentis
Neuron regenerative oral therapy in human testing for Alzheimer's and potentially Parkinson's and other age-related disorders
Why They Buy